Fig. 4From: Characterization and dosimetric predictors for absolute lymphocyte count changes during neoadjuvant chemoradiotherapy with or without pembrolizumab for esophageal squamous cell carcinoma: an analysis of a prospective cohortTypical case of optimized lymphocyte-sparing proton planBack to article page
